Cedars Sinai

Cedars-Sinai, a prominent non-profit academic medical center based in Los Angeles, extends its pioneering work in healthcare beyond its clinical and research operations through Cedars-Sinai Ventures. This strategic venture capital arm is dedicated to investing in early-stage healthcare companies that develop innovative solutions aligning with the medical center's mission of delivering world-class patient care, research, and education. The fund leverages Cedars-Sinai's extensive clinical expertise, research capabilities, and operational infrastructure to support its portfolio companies, offering not just capital but also invaluable strategic guidance and access to a real-world healthcare environment for product development and validation.

Cedars-Sinai Ventures primarily targets early-stage companies across key healthcare sectors, including digital health, medical devices, diagnostics, and therapeutics. Their investment thesis centers on identifying transformative technologies and solutions that have the potential to significantly impact patient outcomes, operational efficiency, and the future of healthcare delivery. While specific check sizes can vary based on the stage and nature of the investment, Cedars-Sinai Ventures typically participates in rounds ranging from Seed to Series B. For instance, they notably led a $10 million Series A round for Health Gorilla, a secure health information exchange platform, demonstrating their capacity to lead significant early-stage investments.

The value proposition of Cedars-Sinai Ventures extends beyond financial capital, offering portfolio companies unique access to a leading medical institution for clinical trials, pilot programs, and expert mentorship. This strategic alignment is a cornerstone of their investment philosophy. While the medical center also operates an accelerator program in partnership with Techstars, Cedars-Sinai Ventures represents a distinct, larger-scale investment vehicle. Based on their participation in various funding rounds, their typical first check size for direct investments ranges from approximately $1,000,000 to $7,000,000. This range allows them to be a meaningful partner in early-stage rounds, as evidenced by their participation in a substantial $100 million Series B round for KelaHealth, an AI-powered clinical decision support system, showcasing their ability to contribute to larger growth rounds as well. Their focus remains on fostering innovation that can be integrated into the broader healthcare ecosystem.